Jazz Commits Up to $4B for T Cell Engagers with AbCellera

Strategic News Watch — June 17, 2026

Jazz Pharmaceuticals committed up to $4 billion to an AbCellera collaboration on next-generation T cell engagers for solid tumors — while two hacking groups hit Novo Nordisk with multi-million-dollar ransom demands and Bristol Myers Squibb posted positive Phase III multiple myeloma data at EHA26.

Today’s top developments:

Jazz Pharmaceuticals will pay up to $4 billion to collaborate with AbCellera on multispecific T cell engagers beyond hematologic malignancies (BioPharma Dive)
Two separate hacking groups obtained sensitive Novo Nordisk data and allegedly attempted to extort multi-million-dollar ransoms (Fierce Pharma)
A prominent venture capitalist publicly opposed proposed U.S. restrictions on biotech investments that could benefit China’s drug industry (STAT)
Bristol Myers Squibb reported positive Phase III mezigdomide and Phase I CAR-T multiple myeloma data at EHA26 (Pharmaceutical Technology)
AviadoBio expanded its exclusive King’s College London license for the vMiX RNAi gene-silencing platform across all human therapeutic areas (Pharmaceutical Technology)
Altaris agreed to acquire model-based drug development software provider Simulations Plus for $375 million in an all-cash transaction (Pharmaceutical Technology)
InStride closed a $30 million Series C led by Echo Health Ventures and FMZ Ventures to scale its pediatric mental health platform (MedCity News)

What to Watch

T Cell Engager Expansion: Jazz-AbCellera’s $4B collaboration targeting solid tumors will test whether next-generation engineering can overcome microenvironment barriers that limited first-gen bispecifics to hematologic malignancies.
Pharma Cybersecurity Vulnerabilities: Novo’s dual ransomware attacks may prompt sector-wide security audits and signal escalating threats to companies with high-value IP and supply chain criticality.
China Investment Restrictions: Proposed federal limitations on U.S.-China biotech deals could reshape global clinical development strategies and force portfolio companies to choose jurisdictional allegiances.
Pharma Software Consolidation: Altaris’s $375M Simulations Plus acquisition signals continued PE interest in model-based drug development tooling; watch for follow-on roll-ups across fragmented modeling, simulation, and PK/PD software vendors as sponsors push for integrated platforms.

This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.

Related Stories

You May Have Missed

Jazz orchestrates a $4bn cancer alliance with AbCellera

Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short